$KRBP
Kiromic Biopharma, Inc.

2019 Q4 Form 10-K Financial Statement

#000155837021003774 Filed on March 31, 2021

View on sec.gov

Income Statement

Concept 2019 Q4 2019 2018 Q4
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.500M
YoY Change 42.05%
% of Gross Profit
Research & Development $1.202M
YoY Change -15.37%
% of Gross Profit
Depreciation & Amortization $87.50K
YoY Change 9.38%
% of Gross Profit
Operating Expenses $3.705M
YoY Change 16.52%
Operating Profit -$3.705M
YoY Change
Interest Expense $22.50K
YoY Change -103.57%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$3.730M
YoY Change -2.36%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.728M
YoY Change -2.41%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$302.3K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.930M
YoY Change 407.89%
Cash & Equivalents $1.929M $1.930M $384.3K
Short-Term Investments
Other Short-Term Assets $90.00K
YoY Change -40.0%
Inventory $22.20K $20.00K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.040M $2.040M
YoY Change 264.29%
LONG-TERM ASSETS
Property, Plant & Equipment $587.9K $590.0K
YoY Change 96.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $24.40K $20.00K
YoY Change 0.0%
Total Long-Term Assets $612.3K $610.0K
YoY Change 90.63%
TOTAL ASSETS
Total Short-Term Assets $2.040M $2.040M
Total Long-Term Assets $612.3K $610.0K
Total Assets $2.653M $2.650M
YoY Change 201.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $452.4K $450.0K
YoY Change 104.55%
Accrued Expenses $220.0K
YoY Change -40.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $673.7K $670.0K
YoY Change 9.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $673.7K $670.0K
Total Long-Term Liabilities $0.00
Total Liabilities $673.7K $670.0K
YoY Change 9.84%
SHAREHOLDERS EQUITY
Retained Earnings -$22.43M
YoY Change
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.979M $1.980M $265.3K
YoY Change
Total Liabilities & Shareholders Equity $2.653M $2.650M
YoY Change 201.14%

Cashflow Statement

Concept 2019 Q4 2019 2018 Q4
OPERATING ACTIVITIES
Net Income -$3.728M
YoY Change -2.41%
Depreciation, Depletion And Amortization $87.50K
YoY Change 9.38%
Cash From Operating Activities -$2.914M
YoY Change 35.53%
INVESTING ACTIVITIES
Capital Expenditures $302.7K
YoY Change -316.21%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$302.7K
YoY Change 116.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.761M
YoY Change 192.11%
NET CHANGE
Cash From Operating Activities -2.914M
Cash From Investing Activities -302.7K
Cash From Financing Activities 4.761M
Net Change In Cash 1.545M
YoY Change -334.06%
FREE CASH FLOW
Cash From Operating Activities -$2.914M
Capital Expenditures $302.7K
Free Cash Flow -$3.217M
YoY Change 60.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001792581
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7332999
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10150500
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1929100
CY2019Q4 us-gaap Inventory Net
InventoryNet
22200
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
588800
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
89100
CY2020Q4 us-gaap Assets Current
AssetsCurrent
10739300
CY2019Q4 us-gaap Assets Current
AssetsCurrent
2040400
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2066000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
587900
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24400
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24400
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q2 dei Entity Public Float
EntityPublicFloat
0
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2863812
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2863812
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7332999
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-39169
CY2020 dei Entity Registrant Name
EntityRegistrantName
Kiromic BioPharma, Inc.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4762913
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
7707 Fannin Street
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 140
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77054
CY2020 dei City Area Code
CityAreaCode
832
CY2020 dei Local Phone Number
LocalPhoneNumber
968-4888
CY2020 dei Security12b Title
Security12bTitle
Common Shares, par value $0.001 per share
CY2020 dei Trading Symbol
TradingSymbol
KRBP
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q4 us-gaap Assets
Assets
12829700
CY2019Q4 us-gaap Assets
Assets
2652700
CY2019 krbp Adjustments To Additional Paid In Capital Warrants Issued Preferred Stock
AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedPreferredStock
3443700
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
673700
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.42
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.39
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4505867
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2862809
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
265300
CY2019 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
407300
CY2019 krbp Stock Issued During Period Preferred Stock New Issues Value
StockIssuedDuringPeriodPreferredStockNewIssuesValue
1056300
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
665200
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
452400
CY2020Q4 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
334200
CY2019Q4 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
221300
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
200
CY2020Q4 us-gaap Loans Payable Current
LoansPayableCurrent
105600
CY2020Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
362400
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1467600
CY2020Q4 us-gaap Liabilities
Liabilities
1467600
CY2019Q4 us-gaap Liabilities
Liabilities
673700
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7332999
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1200
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
52988700
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
13965000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41627800
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22427600
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
11362100
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1979000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12829700
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2652700
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5052900
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1201700
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14144000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2503700
CY2020 us-gaap Operating Expenses
OperatingExpenses
19196900
CY2019 us-gaap Operating Expenses
OperatingExpenses
3705400
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-19196900
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-3705400
CY2020 us-gaap Interest Expense
InterestExpense
3300
CY2019 us-gaap Interest Expense
InterestExpense
22500
CY2020 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
3300
CY2019 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
22500
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19200200
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-3727900
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11400
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
522900
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-3727900
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1979000
CY2020 krbp Stock Issued During Period Preferred Stock New Issues Value
StockIssuedDuringPeriodPreferredStockNewIssuesValue
331700
CY2020 krbp Adjustments To Additional Paid In Capital Warrants Issued Preferred Stock
AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedPreferredStock
2668300
CY2020 krbp Warrants Exercised During Period Value
WarrantsExercisedDuringPeriodValue
4900
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11975400
CY2020 krbp Adjustments To Additional Paid In Capital Warrant Discount Amortization
AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization
19700
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
377000
CY2020 krbp Stock Issued During Period Value Employees And Non Employees
StockIssuedDuringPeriodValueEmployeesAndNonEmployees
9432000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3813700
CY2019 us-gaap Depreciation
Depreciation
87500
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
13245700
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
522900
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1929100
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
220500
CY2020 us-gaap Other Noncash Expense
OtherNoncashExpense
200
CY2019 us-gaap Other Noncash Expense
OtherNoncashExpense
20500
CY2020 us-gaap Inventory Write Down
InventoryWriteDown
22200
CY2020 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
540500
CY2020 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
178100
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3000000
CY2019 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
4500000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15805600
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4761400
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8221400
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1544800
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1929100
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
384300
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10150500
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19200200
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
11362100
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19200200
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-3727900
CY2020 us-gaap Depreciation
Depreciation
200000
CY2019 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-24300
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5900
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
499700
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-46200
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6600
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7700
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
293400
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
112900
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-151300
CY2019 krbp Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-19000
CY2019 krbp Increase Decrease In Convertible Promissory Notes Derivative Liability
IncreaseDecreaseInConvertiblePromissoryNotesDerivativeLiability
2000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6126600
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2913900
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1457600
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
302700
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1457600
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-302700
CY2019 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
250000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
11400
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15000000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2667300
CY2020 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
4900
CY2020 krbp Proceeds From Loan Payable
ProceedsFromLoanPayable
115600
CY2020 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
10000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
74700
CY2020 us-gaap Interest Paid Net
InterestPaidNet
3100
CY2019 us-gaap Notes Issued1
NotesIssued1
134800
CY2019 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
407300
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
143200
CY2019 krbp Preferred Stock Accretion And Settlement Of Dividends
PreferredStockAccretionAndSettlementOfDividends
40000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6126600
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41627800
CY2020Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
12332700
CY2020Q4 krbp Number Of Lease Facility
NumberOfLeaseFacility
1
CY2018Q3 us-gaap Grants Receivable
GrantsReceivable
2235000
CY2019Q3 krbp Phase One Approved Amount Of Grant
PhaseOneApprovedAmountOfGrant
851000
CY2020Q4 krbp Phase Two Approved Amount Of Grant
PhaseTwoApprovedAmountOfGrant
1384000
CY2019Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
10
CY2020Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
3.494
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b>—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, the fair value of convertible promissory notes and the related embedded derivative liability, warrants to purchase common stock underlying shares of Series B Preferred Stock, and estimating services incurred by third-party service providers used to recognize research and development expense.</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Concentrations of Credit Risk and Other Uncertainties</b>—Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">The Company records receivables resulting from activities under its research grant from the NIH. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the granting agency.</p>
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
22200
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2020Q4 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
334200
CY2019Q4 krbp Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
221300
CY2020 krbp Adjustments To Additional Paid In Capital Deferred Ipo Offering Costs
AdjustmentsToAdditionalPaidInCapitalDeferredIpoOfferingCosts
2667300
CY2019Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Depreciation
Depreciation
200000
CY2019 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020 krbp Income From Grants
IncomeFromGrants
142400
CY2019 krbp Income From Grants
IncomeFromGrants
298000
CY2019 krbp Fair Value Changes
FairValueChanges
0
CY2020 krbp Fair Value Changes
FairValueChanges
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19200200
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-3727900
CY2019 krbp Preferred Stock Accretion And Settlement Of Dividends
PreferredStockAccretionAndSettlementOfDividends
40000
CY2020 krbp Preferred Stock Amortization Of Discount
PreferredStockAmortizationOfDiscount
692700
CY2019 krbp Preferred Stock Amortization Of Discount
PreferredStockAmortizationOfDiscount
210600
CY2020 krbp Adjustments To Additional Paid In Capital Warrant Discount Amortization
AdjustmentsToAdditionalPaidInCapitalWarrantDiscountAmortization
19700
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19912600
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3978500
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4505867
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2862809
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.42
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.39
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
587900
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
97462
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1822261
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2627700
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
949600
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
561700
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
361700
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2066000
CY2019 us-gaap Depreciation
Depreciation
87500
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
221300
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
191000
CY2019 krbp Area Of Property Leased
AreaOfPropertyLeased
4100
CY2020Q4 krbp Operating Lease Termination Period After Notice Of Cancellation
OperatingLeaseTerminationPeriodAfterNoticeOfCancellation
P90D
CY2020Q1 krbp Lessee Operating Lease Payments Per Month
LesseeOperatingLeasePaymentsPerMonth
21353
CY2021Q2 krbp Lessee Operating Lease Payments Per Month
LesseeOperatingLeasePaymentsPerMonth
22477
CY2022Q2 krbp Lessee Operating Lease Payments Per Month
LesseeOperatingLeasePaymentsPerMonth
23039
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
265200
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
269700
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
274200
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
230400
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1039500
CY2020 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
262900
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
129100
CY2019Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
10
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
3.494
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2020Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
335982
CY2020Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
1200
CY2020Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1063939
CY2020Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3700
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
839952
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9432000
CY2020Q2 krbp Number Of Votes Per Share
NumberOfVotesPerShare
1
CY2020 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0
CY2019Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10000000
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
858615
CY2020Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
850000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
858615
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1708615
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
270933
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
258813
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2100
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2100
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3842900
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2605400
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3379000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
597400
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
23600
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
27800
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7245500
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3230600
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7061600
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3198100
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
183900
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
32500
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020 krbp Number Of Separate Consulting Agreements
NumberOfSeparateConsultingAgreements
2

Files In Submission

Name View Source Status
0001558370-21-003774-index-headers.html Edgar Link pending
0001558370-21-003774-index.html Edgar Link pending
0001558370-21-003774.txt Edgar Link pending
0001558370-21-003774-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
krbp-20201231.xsd Edgar Link pending
krbp-20201231x10k.htm Edgar Link pending
krbp-20201231x10k001.jpg Edgar Link pending
krbp-20201231x10k002.jpg Edgar Link pending
krbp-20201231x10k003.jpg Edgar Link pending
krbp-20201231x10k004.jpg Edgar Link pending
krbp-20201231x10k005.jpg Edgar Link pending
krbp-20201231x10k006.jpg Edgar Link pending
krbp-20201231x10k007.jpg Edgar Link pending
krbp-20201231x10k008.jpg Edgar Link pending
krbp-20201231x10k009.jpg Edgar Link pending
krbp-20201231x10k010.jpg Edgar Link pending
krbp-20201231x10k011.jpg Edgar Link pending
krbp-20201231x10k012.jpg Edgar Link pending
krbp-20201231x10k013.jpg Edgar Link pending
krbp-20201231x10k014.jpg Edgar Link pending
krbp-20201231x10k015.jpg Edgar Link pending
krbp-20201231x10k016.jpg Edgar Link pending
krbp-20201231x10k017.jpg Edgar Link pending
krbp-20201231x10k_htm.xml Edgar Link completed
krbp-20201231xex21d1.htm Edgar Link pending
krbp-20201231xex23d1.htm Edgar Link pending
krbp-20201231xex31d1.htm Edgar Link pending
krbp-20201231xex31d2.htm Edgar Link pending
krbp-20201231xex32d1.htm Edgar Link pending
krbp-20201231xex32d2.htm Edgar Link pending
krbp-20201231xex4d1.htm Edgar Link pending
krbp-20201231_cal.xml Edgar Link unprocessable
krbp-20201231_def.xml Edgar Link unprocessable
krbp-20201231_lab.xml Edgar Link unprocessable
krbp-20201231_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending